Studies have also found that deletion of Arg2 germline and adoptive transfer of Arg2−/− CD8+ T cells significantly reduced tumor growth in preclinical cancer models by enhancing CD8+ T-cell activation, cytotoxic function, and persistence (48, 119). This evidence concerns the gene CD8A and cancer.